DSIP 5mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of DSIP supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF082025025

Key analytical results include:

• Assay Content: 5.07 mg
• Identification – Retention Time: 0.999
• Identification – Spectrum: 992
• Purity: 99.58 percent
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

DSIP (Delta Sleep-Inducing Peptide) is a small regulatory peptide frequently studied in laboratory environments focused on neurochemical signalling and peptide-mediated physiological regulation.

The compound belongs to a class of short-chain neuropeptides investigated in experimental models exploring biological rhythms, neuroendocrine communication and cellular regulatory signalling.

This preparation contains 5 mg of high purity lyophilized peptide supplied in a sealed research vial. The lyophilization process preserves peptide stability and allows researchers to reconstitute the compound for controlled in vitro experimentation.

Because of its defined peptide sequence and stable analytical profile, DSIP has been referenced in various experimental research models investigating neurochemical signalling pathways.

Compound Overview

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide first identified during research exploring biological sleep regulation and neuroendocrine signalling mechanisms.

The peptide is composed of nine amino acids and has been investigated in laboratory environments studying interactions between neurochemical signalling systems and endocrine regulatory processes.

Research involving DSIP often examines its influence on neuronal signalling pathways, neuroendocrine communication networks and peptide-mediated regulatory mechanisms.

Its compact peptide structure allows researchers to investigate neuropeptide signalling behaviour within controlled experimental models.

Historical Background and Scientific Context

Scientific interest in regulatory neuropeptides expanded significantly during the late twentieth century as advances in neurobiology enabled researchers to identify peptide molecules involved in central nervous system signalling.

DSIP was first described in the 1970s during research examining peptides associated with sleep regulation and neurochemical communication within the brain.

Subsequent research explored the peptide’s interactions with neuroendocrine signalling systems and biological regulatory processes.

Today DSIP remains a subject of experimental research investigating neurochemical signalling pathways and peptide-mediated regulatory mechanisms.

Mechanistic Focus in Research

Within experimental laboratory environments, DSIP is frequently studied in relation to neurochemical signalling pathways and peptide-mediated regulatory mechanisms.

Research investigations commonly explore the compound in experimental models examining:

• Neuropeptide signalling pathways
• Neuroendocrine regulatory mechanisms
• Biological rhythm regulation research
• Intracellular neuronal signalling networks
• Peptide-mediated cellular communication
• Comparative neuropeptide interaction studies
• Experimental neurochemical signalling analysis

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing neuronal communication and peptide signalling behaviour.

Research Applications

In controlled research environments, DSIP may be utilised in experimental models designed to explore neurochemical signalling pathways and peptide regulatory systems.

Examples of research applications include:

• Neuropeptide signalling research
• Neuroendocrine pathway investigation
• Biological rhythm regulatory studies
• Intracellular signalling analysis
• Comparative neuropeptide modelling
• Molecular neurobiology research
• Controlled in vitro peptide signalling studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• 99.58 percent purity with validated assay content
• No detectable heavy metals or microbial contamination
• Endotoxin below 0.001 EU per mg
• Batch GF082025025 – Published October 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.